Eli Lilly (LLY) director Form 3 shows 2,000 shares of common stock held

Rhea-AI Filing Summary

Eli Lilly and Company reported an initial insider ownership filing for a director. The reporting person is identified as a director of Eli Lilly and holds 2,000 shares of the company’s common stock in direct ownership. This type of filing gives investors visibility into how many shares a company insider beneficially owns at the time they become a reporting person.

The document is signed under a power of attorney authorization, indicating that the signature was provided on the director’s behalf. There are no derivative securities, such as options or warrants, listed as beneficially owned in this filing.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bertozzi Carolyn R

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS IN 46285

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/08/2025

3. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jonathan Groff for Carolyn R. Bertozzi, pursuant to authorization attached	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does this Form 3 filing disclose for Eli Lilly (LLY)?

It discloses that a director of Eli Lilly and Company beneficially owns 2,000 shares of the company’s common stock, held directly.

Who is the reporting person in this Eli Lilly (LLY) Form 3?

The reporting person is a director of Eli Lilly and Company, as indicated in the relationship section of the filing.

How many Eli Lilly (LLY) shares does the director own according to this filing?

The director beneficially owns 2,000 shares of Eli Lilly common stock, reported as direct (D) ownership.

Does this Eli Lilly (LLY) Form 3 show any derivative securities?

No, the section for derivative securities does not list any options, warrants, or other derivatives beneficially owned by the director.

What is the purpose of the power of attorney mentioned in the Eli Lilly (LLY) Form 3?

The remarks reference an Exhibit 24 - Power of Attorney, which authorizes another person to sign the Form 3 on the director’s behalf.

Is this Eli Lilly (LLY) Form 3 filed by a single reporting person or a group?

The filing is marked as Form filed by One Reporting Person, indicating it covers only this individual director.